The need for ongoing studies to explore the therapeutic potential and limitations of targeting the FGR-PI3K-AKT-SP1-DKK1 axis extends beyond CRC, encompassing a wider range of cancers. This evidence concerns the gene SP1 and colorectal carcinoma.